Search

Digital twins promise to reshape pharmaceutical development and manufacturing by creating virtual replicas that mirror physical systems over time. Their value lies in linking process knowledge, real-time data, predictive modelling, and decision support into a single operational framework. In pharmaceutical contexts, this promise is especially relevant because product quality is tightly coupled to process history, material attributes, and patient-facing performance. The core problem is that digital twin development in pharma remains fragmented across manufacturing, drug delivery, regulatory modelling, and digital transformation literatures. Manufacturing studies often focus on process control, PAT, and continuous production, whereas drug delivery studies emphasise physiological prediction, formulation performance, and patient-specific behaviour. These areas share mechanistic foundations, but they are rarely treated as parts of a unified pharmaceutical digital twin ecosystem. This conceptual review analyses digital twin logic across pharmaceutical manufacturing and drug delivery systems. It focuses on how mechanistic models, hybrid modelling, and real-time data infrastructures can be combined to support quality, performance prediction, and regulatory decision-making. The central argument is that digital twins must become not only predictive but also explainable and governable. The synthesis defines the architecture of pharmaceutical digital twins, catalogues their manufacturing and drug delivery applications, and identifies unresolved challenges in model coupling, parameter identifiability, uncertainty handling, and regulatory credibility. It also maps technological, organisational, economic, and regulatory barriers that prevent promising models from becoming routine industrial tools. Five tables summarise the conceptual architecture, application domains, model architectures, integration problems, and implementation barriers. Realising the full potential of pharmaceutical digital twins will require mechanistic rigour, explainable analytics, high-quality data connectivity, and early alignment with regulatory expectations. The future of the field will depend less on isolated demonstrations and more on reusable validation strategies, transparent model governance, and cross-sector collaboration. Digital twins should therefore be understood as evolving regulatory-scientific infrastructures rather than as standalone computational artefacts.

The translation of drug delivery innovations from laboratory design to clinical application remains uncertain, expensive, and highly selective. Many systems demonstrate promising biological activity in early studies but fail to progress because evidence of manufacturability, safety, stability, or regulatory maturity is incomplete. This creates a recurring gap between technical novelty and clinical readiness. Existing technology readiness models provide useful language for describing maturity, but they were not originally designed for pharmaceutical technologies. Drug delivery systems require simultaneous assessment of material attributes, formulation behaviour, biological performance, dose reproducibility, scale-up potential, and patient-facing utility. A single linear maturity scale is therefore insufficient for classifying readiness before first-in-human development. This article develops a novel conceptual model called the Pharmaceutical Technology Readiness Matrix. The model integrates technology readiness logic, drug delivery innovation categories, and preclinical translation criteria into a structured assessment framework. Its purpose is to support transparent classification, risk assessment, and decision-making before clinical translation. The proposed matrix adapts readiness levels for drug delivery technologies, classifies major innovation categories, defines preclinical translation criteria, and links evidence maturity to risk and Go/No-Go decisions. Five tables specify the readiness levels, innovation categories, translation criteria, matrix design, and decision pathway. Together, these elements provide a practical conceptual tool for comparing heterogeneous delivery technologies. The Pharmaceutical Technology Readiness Matrix may help researchers, investors, developers, and regulators evaluate drug delivery systems more consistently. By making evidence gaps explicit before clinical translation, the model aims to reduce avoidable attrition and guide rational allocation of development resources. Future empirical validation will be required to test its predictive value across delivery platforms and therapeutic areas.

Smart drug delivery systems promise to transform therapy by linking drug release to physiological need, local microenvironmental cues, or algorithmic feedback. Their ambition is not merely to administer medicines more conveniently, but to create therapeutic platforms that sense, decide, and act. Yet this promise remains vulnerable to sensor errors, biological noise, material instability, actuator failure, and unpredictable patient behaviour. The dominant design philosophy in smart delivery has been shaped by precision, specificity, and near-perfect triggering. Systems are often evaluated as though the correct signal will be detected, the intended release pathway will activate, and the therapeutic response will follow the modelled trajectory. This assumption makes many platforms appear elegant in controlled studies but fragile in messy clinical environments. This perspective argues that smart drug delivery needs a failure-tolerant design paradigm. Rather than treating malfunction as an exceptional event to be eliminated, failure-tolerant design treats drift, delay, degradation, and misclassification as expected operating conditions. The aim is not to abandon precision, but to make precision recoverable when the system deviates from its intended state. The framework proposed here integrates control logic, risk engineering, and pharmaceutical performance principles. Control logic supplies feedback, fault detection, and adaptive recovery; risk engineering supplies structured failure anticipation and mitigation; pharmaceutical performance anchors every decision in pharmacokinetics, pharmacodynamics, material stability, and patient use. Together, these domains can move smart drug delivery beyond the brittle ideal of error-free function. The central claim is that smart drug delivery systems should be designed to fail intelligently. A clinically useful system must detect its own unreliability, degrade toward a safer state, activate independent recovery pathways, and preserve therapeutic performance within acceptable bounds. Such a shift would require new engineering practice, new regulatory expectations, and a more honest understanding of biological variability.

Programmable drug delivery systems are emerging as a transformative class of therapeutic technologies because they can adjust drug release according to physiological signals, algorithmic rules, or external commands. Their appeal lies in the promise of more responsive, individualised, and continuous therapy than is possible with conventional dosage forms. Closed-loop insulin delivery, implantable programmable pumps, responsive antidote systems, and digitally mediated delivery platforms all illustrate this shift from passive administration to active therapeutic control. This shift also changes the ethical character of drug delivery. When a device senses, interprets, and acts on behalf of a patient, dosing becomes partly delegated to software, control architecture, and design assumptions. The ethical question is therefore not only whether the system works, but whether it preserves the patient’s agency while pursuing therapeutic optimisation. The core problem is that programmable delivery systems combine pharmacological intervention, medical device operation, data processing, and algorithmic decision-making in a single therapeutic object. This convergence creates tensions between efficiency and autonomy, adaptability and safety assurance, and automation and human oversight. Existing ethical and regulatory vocabularies do not fully capture these tensions because they often treat drugs, devices, software, and clinical decisions as separable domains. This critical perspective argues that programmable drug delivery requires an ethical design approach from the earliest stages of development. Autonomy must be translated into design features such as consent clarity, override capacity, patient-facing explanation, and withdrawal options. Safety must be treated as a lifecycle property rather than a static pre-market claim. The article proposes a critical framework for classifying programmable delivery systems according to autonomy level, identifying ethical pressure points, and linking them to design and governance requirements. It argues that trustworthy programmable delivery depends not merely on technical performance, but on the deliberate preservation of meaningful human control. Ethical foresight must therefore become part of the engineering logic of programmable drug delivery itself.

Advanced drug delivery now includes lipid nanoparticles, polymeric carriers, implants, and 3D-printed dosage forms, each offering distinct advantages for controlling where, when, and how drugs are released. These platforms differ in their suitability for nucleic acids, small molecules, biologics, local therapy, systemic exposure, long-acting treatment, and personalised dosing. The breadth of available options has expanded faster than the decision tools used to choose among them. Platform selection is often driven by familiarity, institutional capability, technological enthusiasm, or precedent within a therapeutic area. Such heuristic decisions can produce poor alignment between the drug, the target product profile, the patient population, and the manufacturing pathway. A structured framework is therefore needed to make platform choice more transparent, reproducible, and development-relevant. This article constructs an original decision framework for selecting among lipid nanoparticles, polymeric carriers, implants, and 3D-printed dosage platforms. The framework treats platform choice as a multi-criteria decision problem rather than as a single-attribute optimisation exercise. It integrates drug properties, release requirements, stability, scalability, usability, regulatory precedent, and cost into a practical selection process. A criteria-driven platform selection process can help development teams avoid technology-led formulation choices and instead align delivery strategy with therapeutic purpose. The proposed framework is intended to support early-stage screening, translational planning, quality-by-design discussions, and portfolio decisions. Its central argument is that no advanced delivery platform is inherently superior; the best platform is the one that best satisfies the target product profile under real development constraints.

Scalable drug delivery platforms are increasingly central to pharmaceutical innovation because they can shorten development timelines, support repeated product generation, and enable broader access when manufacturing and regulatory pathways are sufficiently stable. Yet the term “platform” is often applied before a technology has demonstrated repeatable transfer across products, indications, and production environments. This creates uncertainty about whether a delivery technology is truly mature or simply promising. Existing maturity concepts offer useful starting points but do not fully capture the pharmaceutical specificity of drug delivery platforms. Generic technology readiness models tend to emphasise proof of concept, whereas manufacturing readiness frameworks focus on production capability. Pharmaceutical platform maturity requires a broader view that also includes formulation robustness, patient-facing performance, quality system integration, regulatory precedent, and lifecycle adaptability. This article develops a conceptual model for defining and assessing pharmaceutical platform maturity in scalable drug delivery technologies. The proposed Pharmaceutical Platform Maturity Model integrates product-level, process-level, and regulatory-level maturity into a single interpretive framework. The model is designed to distinguish early innovation from repeatable platform capability. The model defines scalable delivery technology criteria, identifies maturity indicators across three interdependent dimensions, and proposes a five-level maturity scale ranging from concept to commoditised platform. Four tables support the argument by contrasting existing assessment frameworks, defining scalability criteria, summarising maturity indicators, and presenting the integrated maturity rubric. The model is intended as a strategic, analytical, and communicative tool. The article concludes that platform maturity should not be inferred from clinical success, manufacturing feasibility, or regulatory approval alone. A drug delivery platform becomes mature only when product performance, process control, and regulatory confidence co-evolve into a repeatable system. This integrated perspective can help developers, investors, regulators, and technology assessors evaluate scalable delivery technologies more consistently.

Advanced drug delivery systems have long promised to transform therapy by improving biodistribution, reducing toxicity, enabling intracellular delivery, extending exposure, and opening therapeutic spaces that conventional dosage forms cannot reach. Yet the field remains marked by a persistent translation paradox: thousands of sophisticated carrier systems are reported in the literature, while only a small fraction progress into durable clinical products. This gap is usually explained through biological complexity, manufacturing difficulty, regulatory uncertainty, or inadequate preclinical models. This critical perspective proposes that these explanations, although important, are incomplete. A deeper systemic factor is technological lock-in, defined here as the self-reinforcing dominance of specific drug delivery platforms that shape what researchers, funders, manufacturers, regulators, and companies consider technically feasible and translationally credible. Once a platform accumulates expertise, protocols, supply chains, regulatory familiarity, and publication momentum, alternatives may struggle to compete even when they offer potentially superior solutions. The central argument is that technological lock-in contributes to translational failure by narrowing the drug delivery imagination. Instead of asking which delivery architecture is best suited to a given biological, clinical, manufacturing, and regulatory problem, the field often asks how an incumbent platform can be modified to fit yet another therapeutic challenge. This platform-first logic can lead to repeated optimisation of familiar systems while more disruptive or simpler design spaces remain underexplored. The article critically examines the assumptions that sustain dominant platforms in advanced drug delivery. These assumptions include beliefs that increasing carrier complexity necessarily improves therapeutic performance, that certain materials possess broad translational privilege, that murine and in vitro models can adequately predict human outcomes, and that incremental optimisation is less risky than platform diversification. The perspective argues that these assumptions are not merely technical claims but institutional habits that stabilise lock-in. The proposed conceptual model links critical assumptions, technological lock-in, platform dependency, innovation constraint, and translational failure in a self-reinforcing cycle. In this model, failure does not necessarily disrupt dominant platforms; paradoxically, it may intensify dependence on them because they remain the most familiar, fundable, publishable, manufacturable, and regulatable options. Five tables structure the analysis by summarising translational failure evidence, critical assumptions, failure mechanisms, lock-in case examples, and the proposed model. Breaking technological lock-in requires more than improving individual formulations. It requires deliberate diversification of platform portfolios, stronger interrogation of inherited assumptions, translational assessment that rewards fit-for-purpose simplicity, and innovation policies that lower the cost of exploring alternative delivery architectures. A more resilient advanced drug delivery ecosystem should treat platform diversity not as inefficiency, but as insurance against repeated translational failure.

Advanced drug delivery systems promise more precise, durable, and patient-centred therapy through nanomedicines, long-acting formulations, implantable platforms, smart delivery devices, and personalised dosage forms. These technologies can reduce dosing burden, improve therapeutic control, and expand the design space of pharmaceutical care. Yet the same sophistication that makes them attractive can also make them expensive, infrastructure-dependent, and difficult to use. The equity implications of these technologies therefore require systematic attention. The central problem addressed in this article is that pharmaceutical innovation is often evaluated through performance, safety, manufacturability, and market value, while equity remains treated as a downstream access issue. This creates a risk that advanced drug delivery systems will reach populations already well served by health systems while excluding communities facing poverty, geographic isolation, disability, low literacy, weak infrastructure, or limited digital access. Equity cannot be repaired only after launch if exclusion has already been built into the technology. It must be considered during design, development, evaluation, pricing, procurement, and implementation. This article develops the concept of pharmaceutical technology equity as a deliberate design and policy goal for advanced drug delivery systems. It argues that equitable pharmaceutical technology requires simultaneous attention to access, affordability, and usability. Access concerns whether the technology can physically and institutionally reach the people who need it. Affordability concerns whether patients and health systems can obtain it without unacceptable financial burden, while usability concerns whether diverse users can safely and effectively engage with the product in real settings. The article defines pharmaceutical technology equity, identifies structural barriers, and proposes design principles for inclusive advanced drug delivery systems. Four tables support the argument by defining equity logic, cataloguing access barriers, mapping design principles, and presenting a decision-oriented framework. The core conclusion is that equity must become an explicit and measurable goal of pharmaceutical technology development. Advanced drug delivery should not merely produce better products for privileged users; it should expand therapeutic capability for populations historically excluded from high-value innovation.

Drug delivery has become one of the most technically inventive areas of pharmaceutical science, producing increasingly elaborate platforms such as multifunctional nanoparticles, long-acting depots, 3D-printed dosage forms, implantable systems, and responsive materials. Yet the number of delivery technologies that successfully become routine clinical and commercial products remains small compared with the volume of experimental innovation. This mismatch creates a translational paradox at the centre of the field. This article argues that the paradox cannot be explained only by external barriers such as regulation, investment scarcity, or clinical conservatism. It also reflects an internal innovation logic that equates sophistication with value. In this logic, the most admired systems are often those with the most components, functions, triggers, layers, and claims of precision. The article develops an original critical theory of over-engineering in drug delivery. Over-engineering is defined as the addition of technical features, materials, control mechanisms, or architectural complexity beyond what is necessary for therapeutic function, manufacturability, usability, and economic viability. The central claim is that excessive complexity can reduce, rather than increase, translational probability. Through a critical theoretical synthesis of recent drug delivery and translational literature, the paper identifies mechanisms through which over-engineered systems become difficult to manufacture, characterise, regulate, finance, prescribe, and use. It argues that translational failure is not merely an unfortunate downstream event but is often designed into systems at the earliest conceptual stage. Complexity therefore becomes a hidden liability disguised as innovation. The article proposes a counter-logic of design simplification. This counter-logic does not reject sophisticated science, but it demands that sophistication be justified by translational necessity rather than aesthetic or academic appeal. The conclusion calls for a simplicity revolution in drug delivery, where the field learns to value robustness, manufacturability, usability, and patient access as highly as novelty.

To evaluate patient-derived organoids as a translational testing platform for bio-nano drug delivery systems, this study examined whether organoid assays could predict therapeutic efficacy, identify organ-specific toxicity, and support patient-specific nanomedicine selection. The central objective was to determine whether tumor and matched normal organoids could resolve formulation-dependent differences that are often obscured in conventional two-dimensional cultures. Five bio-nano platforms, comprising lipid nanoparticles, polymeric micelles, gold nanorods, mesoporous silica nanoparticles, and liposomes, were systematically exposed to six patient-derived organoid lines representing colorectal, pancreatic, and lung cancer with matched normal intestinal, pancreatic, and airway organoids. High-content imaging, ATP-based viability testing, cleaved-caspase apoptosis quantification, confocal penetration mapping, epithelial barrier measurements, and cytokine profiling were performed. Organoid drug sensitivity scores were integrated with nanoparticle physicochemical attributes and genomic annotations. The organoid panel discriminated nanocarrier efficacy across tumor types, with targeted lipid nanoparticles and polymeric micelles producing the strongest selective tumor killing. Gold nanorods showed deep penetration but limited drug-release-associated efficacy, whereas mesoporous silica nanoparticles produced mixed efficacy with elevated inflammatory signaling in normal organoids. Personalized benefit-risk ranking identified different optimal nanocarriers for each patient-derived model, demonstrating clinically relevant interpatient heterogeneity. Organoid-based testing provides a scalable and patient-relevant strategy for evaluating bio-nano drug delivery systems before clinical translation. By combining efficacy, toxicity, penetration, and patient-specific sensitivity metrics, this platform may reduce late-stage nanomedicine failure and support individualized therapy selection.

Adaptive drug delivery has often been imagined as a technologically advanced system in which sensors, software, power sources, and feedback algorithms continuously monitor biological conditions and adjust therapy. This vision has stimulated important innovation, but it has also encouraged the assumption that adaptation requires electronic intelligence. In many pharmaceutical contexts, this assumption may unnecessarily increase complexity, cost, and technical fragility. A different design logic is possible. Dosage forms can respond to physiological environments through the intrinsic behavior of materials rather than through real-time electronic sensing. Such systems do not measure, calculate, or transmit information digitally; instead, they translate local biological conditions into physical or chemical changes that modulate drug release. This article develops a theory-driven framework for passive adaptive dosage forms. It distinguishes passive responsiveness from active sensor-driven feedback and defines adaptation as an emergent property of material–environment interaction. The framework is intended for non-electronic dosage forms that use physiological cues such as pH, enzymes, glucose, redox gradients, temperature, or mechanical stress to regulate release. The article synthesizes evidence and concepts from stimuli-responsive polymers, hydrogels, molecularly imprinted polymers, shape-memory systems, glucose-responsive platforms, and self-oscillating gels. It does not present new empirical data. Instead, it uses existing literature to clarify the design principles needed to treat passive responsiveness as a deliberate pharmaceutical strategy. Passive adaptive dosage forms offer a simpler and potentially more translatable route to adaptive therapy. Their promise lies not in replacing all electronic systems, but in expanding the adaptive delivery paradigm beyond sensors and circuits. By foregrounding material-based triggering and release behavior design, the article positions passive responsiveness as a distinct and underdeveloped class of pharmaceutical system design.